# Holly B. Krasa

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/holly-b-krasa/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,471 |
| Field | Genetic and Kidney Cyst Diseases |
| h-index | 28 |
| i10-index | 40 |
| Last Known Institution | ActionAid |
| OpenAlex ID | https://openalex.org/A5088051058 |
| ORCID iD | 0000-0003-2258-8020 |
| Works | 79 |

## Researcher papers

- [Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease](https://scholariq.org/papers/tolvaptan-in-patients-with-autosomal-dominant-polycystic-kidney-disease/)
- [Prevalence of autosomal dominant polycystic kidney disease in the European Union](https://scholariq.org/papers/prevalence-of-autosomal-dominant-polycystic-kidney-disease-in-the-european-union/)
- [Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database](https://scholariq.org/papers/clinical-pattern-of-tolvaptan-associated-liver-injury-in-subjects-with-autosomal/)
- [Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction](https://scholariq.org/papers/acute-hemodynamic-effects-of-tolvaptan-a-vasopressin-v2-receptor-blocker-in/)
- [Continental Differences in Clinical Characteristics, Management, and Outcomes in Patients Hospitalized With Worsening Heart Failure](https://scholariq.org/papers/continental-differences-in-clinical-characteristics-management-and-outcomes-in/)
- [Clinical Course of Patients With Hyponatremia and Decompensated Systolic Heart Failure and the Effect of Vasopressin Receptor Antagonism With Tolvaptan](https://scholariq.org/papers/clinical-course-of-patients-with-hyponatremia-and-decompensated-systolic-heart/)
- [Endocrine Alterations That Underlie Endotoxin-Induced Disruption of the Follicular Phase in Ewes1](https://scholariq.org/papers/endocrine-alterations-that-underlie-endotoxin-induced-disruption-of-the/)
- [Tolvaptan in Autosomal Dominant Polycystic Kidney Disease](https://scholariq.org/papers/tolvaptan-in-autosomal-dominant-polycystic-kidney-disease/)
- [Endotoxin Inhibits the Reproductive Neuroendocrine Axis While Stimulating Adrenal Steroids: A Simultaneous View from Hypophyseal Portal and Peripheral Blood<sup>1</sup>](https://scholariq.org/papers/endotoxin-inhibits-the-reproductive-neuroendocrine-axis-while-stimulating/)
- [Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease](https://scholariq.org/papers/short-term-effects-of-tolvaptan-on-renal-function-and-volume-in-patients-with/)
- [Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, and Outcomes in Autosomal Dominant Polycystic Kidney Disease](https://scholariq.org/papers/patient-reported-outcomes-measures-polycystic-kidney-disease-burden-and-outcomes/)

## Researcher topics

- [Genetic and Kidney Cyst Diseases](https://scholariq.org/topics/genetic-and-kidney-cyst-diseases/)
- [Electrolyte and hormonal disorders](https://scholariq.org/topics/electrolyte-and-hormonal-disorders/)
- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)
- [Cardiac Valve Diseases and Treatments](https://scholariq.org/topics/cardiac-valve-diseases-and-treatments/)
- [Pulmonary Hypertension Research and Treatments](https://scholariq.org/topics/pulmonary-hypertension-research-and-treatments/)

## Researcher university

- [ActionAid](https://scholariq.org/institutions/actionaid/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.